➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
AstraZeneca
Dow
Mallinckrodt

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

NOVOLOG MIX 70/30 PENFILL Drug Profile


Email this page to a colleague

« Back to Dashboard

Summary for Tradename: NOVOLOG MIX 70/30 PENFILL
Patents:12
Applicants:1
BLAs:1
Suppliers: see list3

Company Disclosures: US Patents for NOVOLOG MIX 70/30 PENFILL

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Basgsvaerd, DK) 2013-08-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Bagsvaerd, DK) 2014-12-02 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172 002 2002-05-03   Try Before You Buy Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for NOVOLOG MIX 70/30 PENFILL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 41/2005 Austria   Try Before You Buy PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LÖSLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHÄLTNIS 70:30
32/2000 Austria   Try Before You Buy PRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623
132006901385693 Italy   Try Before You Buy PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTAMINATA NEL RAPPORTO 70/30(NOVOMIX 70); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/017-018-019-020-021-022, 20051005
SPC026/2000 Ireland   Try Before You Buy SPC026/2000: 20031215, EXPIRES: 20150622
132000900885237 Italy   Try Before You Buy AUTHORISATION NUMBER(S) AND DATE(S): (VEDI NOTE), 20000801;- - -, 20181206
40/2005 Austria   Try Before You Buy PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005
300021 Netherlands   Try Before You Buy 300021, 20140621, EXPIRES: 20150622
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Harvard Business School
Mallinckrodt
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.